Skip to main content

Table 5 Changes in lipid parameters in all patients and patients grouped according to treatment order

From: Safety and efficacy of long-term combination therapy with bezafibrate and ezetimibe in patients with dyslipidemia in the prospective, observational J-COMPATIBLE study

Parameter n Baseline LOCF Change % p-value
LDL-C       
Total 249 136.2 ± 36.6 112.5 ± 27.4 −23.7 ± 36.1 −17.4 <0.001
EZE + BEZA 67 120.0 ± 31.1 110.5 ± 22.9 −9.4 ± 31.7 −7.8 0.017
BEZA + EZE 99 143.6 ± 32.4 114.6 ± 25.1 −29.1 ± 29.0 −20.3 <0.001
BEZA & EZE 83 140.6 ± 41.5 111.6 ± 33.0 −29.0 ± 43.5 −20.6 <0.001
HDL-C       
Total 445 52.1 ± 14.2 56.7 ± 14.3 4.6 ± 11.2 8.8 <0.001
EZE + BEZA 138 52.5 ± 14.4 58.2 ± 14.8 5.7 ± 10.3 10.9 <0.001
BEZA + EZE 164 53.0 ± 15.2 55.4 ± 14.3 2.4 ± 12.0 4.5 0.012
BEZA & EZE 143 50.6 ± 12.6 56.9 ± 13.7 6.3 ± 10.9 12.5 <0.001
TG       
Total 483 266.6 ± 210.1 158.6 ± 112.2 −108.0 ± 181.3 −40.5 <0.001
EZE + BEZA 143 274.9 ± 169.0 147.6 ± 77.8 −127.3 ± 149.7 −46.3 <0.001
BEZA + EZE 183 244.0 ± 193.0 166.0 ± 125.0 −78.0 ± 193.7 −32.0 <0.001
BEZA & EZE 157 285.4 ± 256.7 160.1 ± 122.2 −125.2 ± 189.0 −43.9 <0.001
Non-HDL-C       
Total 293 183.5 ± 41.8 143.8 ± 32.4 −39.6 ± 40.9 −21.6 <0.001
EZE + BEZA 85 168.2 ± 33.2 142.7 ± 30.0 −25.5 ± 33.2 −15.2 <0.001
BEZA + EZE 112 187.3 ± 43.1 144.1 ± 29.2 −43.1 ± 39.2 −23.0 <0.001
BEZA & EZE 96 192.5 ± 43.7 144.5 ± 38.0 −48.0 ± 46.0 −24.9 <0.001
  1. Data are expressed as mean ± standard deviation. “Change” indicates the change from baseline to the LOCF value. “%” indicates rate of change from baseline to the LOCF. The paired t test was used to examine the significance of within-group changes. LDL-C was estimated using the Friedewald formula. LOCF: last observation carried forward; EZE + BEZA: patients who were already taking ezetimibe and then added bezafibrate at the start of the study; BEZA + EZE: patients who were already taking bezafibrate and then added ezetimibe at the start of the study; BEZA & EZE: patients who started bezafibrate and ezetimibe concurrently.